Perspective Therapeutics Doses First Patient In New [212Pb]VMT01 + Nivolumab Advances With Combination Arm In Metastatic Melanoma Patients

Perspective Therapeutics, Inc., announced that the first patient has been dosed in a new cohort of its Phase 1/2a trial evaluating [212Pb]VMT01, a targeted alpha-particle therapy (TAT), for metastatic melanoma. This study focuses on patients with previously treated, histologically confirmed melanoma who also show positive melanocortin 1 receptor (MC1R) imaging scans.

"The progress of our [212Pb]VMT01 program continues to reinforce our belief in its potential to transform treatment for patients with difficult-to-treat cancers. By moving into this next cohort, we are expanding our understanding of the therapeutic window of [212Pb]VMT01 and how best to optimize efficacy and safety in a combination regimen with a PD-1 inhibitor, including contribution of effect by each component of the regimen. Through this program, we are also learning about the potential for synergy between our proprietary 212Pb emitting constructs and PD-1 inhibition. Each step forward brings us closer to providing a novel treatment option for patients with limited alternatives," said Thijs Spoor, Chief Executive Officer of Perspective. 

In this new trial arm, patients are receiving [212Pb]VMT01 at 3.0 mCi in combination with nivolumab (Opdivo®), Bristol Myers Squibb’s PD-1 inhibitor. Perspective has also reopened enrollment for its 3.0 mCi [212Pb]VMT01 monotherapy cohort. The Safety Monitoring Committee (SMC) recommended escalating to the higher dose after reviewing encouraging safety data from earlier cohorts at 1.5 mCi, both as monotherapy and in combination with nivolumab.

"With the initiation of this second combination cohort, we are building on encouraging early safety and anti-tumour activity observed for [212Pb]VMT01. Advancing to a higher dose level with [212Pb]VMT01 alongside nivolumab represents an important step in evaluating the promising potential of this targeted alpha therapy in combination with immune checkpoint inhibition for patients with advanced melanoma," commented Markus Puhlmann, Chief Medical Officer of Perspective. 

Metastatic melanoma remains a difficult-to-treat cancer, with approximately 100,000 new U.S. cases and 8,300 deaths annually. Despite advances in immunotherapies, patients who relapse after frontline treatment face limited survival prospects, with median progression-free survival for current second-line options often ranging between 2–5 months. Perspective’s targeted radiopharmaceutical approach aims to address this high unmet medical need by combining precision imaging with novel alpha-particle therapy.